A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Must be ≥18 years of age

• Must have histologically or cytologically confirmed diagnosis as follows:

1. Monotherapy Phase 1: A locally advanced unresectable or metastatic solid tumormalignancy that harbors a RAS (KRAS, NRAS, or HRAS) activating mutation.

2. Monotherapy Phase 2a: A locally advanced unresectable or metastatic solid tumormalignancies: pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, orRAS-mutant non-small cell lung cancer (NSCLC)

3. Combination therapy (both phases): A locally advanced unresectable ormetastatic PDAC

• Participants must be treatment naive or received prior systemic standard-of-caretreatment as follows:

1. Monotherapy Phase 1: received at least 1 line of systemic standard-of-caretreatment for their advanced or metastatic disease

2. Monotherapy Phase 2a:

3. First-line PDAC participants will have received no previous systemicanti-cancer therapy. Second-line PDAC participants will have received nomore than one prior systemic anti-cancer therapy.

4. First-line melanoma participants will have received no previous systemicanti-cancer therapy. Second- and third-line participants will havereceived and failed one or two prior systemic anti-cancer therapies,respectively.

5. NSCLC participants will have received at least one and no more than twoprevious lines of systemic therapy.

6. Combination therapy (both phases): PDAC participants will have received noprevious systemic anti-cancer therapy for their advanced or metastatic disease.

• Must have evidence of measurable disease (at least one target lesion) per RECISTv1.1 criteria

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Adequate organ function

Exclusion Criteria:

• Inability to swallow oral medications

• Symptomatic, untreated, or actively progressing known central nervous system (CNS)metastases

• History or concurrent evidence of retinal vein occlusion (RVO) or current riskfactors for RVO. History of serous retinopathy, retinal edema, or retinal pigmentepithelial detachment (RPED)

• Impaired cardiovascular function or clinically significant cardiac disease

• History of rhabdomyolysis within 3 months prior to start of study treatment

• Active skin disorder requiring systemic treatment within 3 months prior to the startof study treatment

• Females who are pregnant, breastfeeding, or planning to become pregnant and maleswho plan to father a child while enrolled in this study.